"10.1371_journal.pone.0077138","plos one","2013-10-30T00:00:00Z","Allison Martin; Cecilia L Moore; Patrick W G Mallon; Jennifer F Hoy; Sean Emery; Waldo H Belloso; Praphan Phanuphak; Samuel Ferret; David A Cooper; Mark A Boyd; on behalf of the Second-line study team","The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia; University College Dublin School of Medicine and Medical Science, Dublin, Ireland; The Alfred Hospital and Monash University, Victoria, Melbourne, Australia; Coordinación de Investigación Clínica Académica en Latinoamérica, Buenos Aires, Argentina; Thai Red Cross AIDS Research Center, Bangkok, Thailand; Hopital Saint-Louis, Paris, France","Conceived and designed the experiments: AM PWGM JFH SE MAB. Performed the experiments: AM MAB PP. Analyzed the data: CLM. Wrote the paper: AM CLM PWGM JFH SE WHB PP SF DAC MAB. Conceived the study: PWGM SE MAB. Designed the concept and analysis plan: AM PWGM JFH SE MAB. Oversaw the conduct of the study, including all data acquisition: AM MAB. Drafted the manuscript: AM. Reviewed the analysis plan and manuscript: CLM PWGM JFH SE WHB PP SF DAC MAB. Member of the Protocol Steering Committee that developed and oversaw the protocol: WHB PP SF DAC.","The Kirby Institute, Merck & Co. Inc., AbbVie Pty Ltd, amfAR, and NHMRC specifically funded this study. The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. Mark Boyd was paid to prepare and present educational materials for Boehringer-Ingelheim, Gilead, Janssen-Cilag and Merck Sharpe, and Dohme. Jennifer Hoys institution has received funding for investigator-initiated research, service on advisory boards, lectures and conference sponsorship from Janssen-Cilag, Gilead Sciences, Merck Sharpe and Dohme, and ViiV Healthcare. Sean Emery has received research funding from Abbott, Gilead, Pfizer, Merck Sharpe and Dohme and ViiV Healthcare. David Cooper has received AbbVie and Merck Sharpe and Dohme grants, consultant and speaker fees. Patrick Mallon has received support in honoraria, research grants, lecture sponsorships and advisory boards from Abbott, Merck Sharpe and Dohme, Bristol Myers Squibb, Pfizer, Gilead, Glaxo-Smith Kline, Janssen-Cilag, and ViiV Healthcare. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","10","Allison Martin","AM",11,TRUE,5,3,1,10,TRUE,FALSE,TRUE,1,"11",TRUE
